Lakewood-Amedex holder reports 8.8% stock stake

Lakewood-Amedex Biotherapeutics Inc. reports that WFI Equity, LLC has filed as a significant holder of its common stock.

Rhea-AI Filing Summary

Lakewood-Amedex Biotherapeutics Inc. reports that WFI Equity, LLC has filed as a significant holder of its common stock. WFI Equity beneficially owns 1,259,684 shares of common stock, representing 8.8% of the class, with sole voting and sole dispositive power over all of these shares and no shared power. The ownership percentage is based on 14,320,366 shares of common stock outstanding as of April 23, 2026, as referenced from a prior Form S-1. The filing is signed by Bradford Charles Lichota as Manager of WFI Equity, LLC.

Key Figures

Shares beneficially owned: 1,259,684 shares Percent of class: 8.8% Shares outstanding: 14,320,366 shares +2 more

5 metrics

Shares beneficially owned 1,259,684 shares Common stock beneficially owned by WFI Equity, LLC

Percent of class 8.8% Ownership percentage of Lakewood-Amedex common stock held by WFI Equity, LLC

Shares outstanding 14,320,366 shares Common stock outstanding as of April 23, 2026, used for percentage calculation

Sole voting power 1,259,684 shares Shares over which WFI Equity, LLC has sole power to vote

Sole dispositive power 1,259,684 shares Shares over which WFI Equity, LLC has sole power to dispose

Key Terms

beneficially owned, sole voting power, dispositive power, Schedule 13G

4 terms

beneficially owned financial

"Amount beneficially owned: 1,259,684"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole voting power financial

"Sole Voting Power 1,259,684.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 1,259,684.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"Percent of class: 8.8% reported on Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in LABT does WFI Equity, LLC report on this Schedule 13G?

WFI Equity, LLC reports beneficial ownership of 1,259,684 shares of Lakewood-Amedex Biotherapeutics Inc. (LABT) common stock, representing 8.8% of the outstanding class, based on 14,320,366 shares outstanding as of April 23, 2026.

Does WFI Equity, LLC have sole or shared voting power over its LABT shares?

WFI Equity, LLC reports sole voting power over all 1,259,684 LABT shares it beneficially owns and no shared voting power. It likewise has sole dispositive power over these shares and no shared dispositive power.

How was the 8.8% ownership percentage in LABT calculated for WFI Equity, LLC?

The 8.8% ownership figure is calculated using a total of 14,320,366 LABT common shares outstanding as of April 23, 2026, which Lakewood-Amedex Biotherapeutics Inc. referenced in a Form S-1 filed on May 1, 2026.

Who signed the Schedule 13G filing related to LABT for WFI Equity, LLC?

The filing for Lakewood-Amedex Biotherapeutics Inc. (LABT) was signed by Bradford Charles Lichota in his capacity as Manager of WFI Equity, LLC, dated August 14, 2026.

What type of security in LABT does WFI Equity, LLC report owning?

WFI Equity, LLC reports beneficial ownership of common stock of Lakewood-Amedex Biotherapeutics Inc. (LABT). The filing specifies the title of the class as common stock with CUSIP 51255A201.

Where is WFI Equity, LLC, the LABT shareholder, organized and located?

WFI Equity, LLC is a Michigan limited liability company with its principal business office at 320 N. Main St., Suite 200, Ann Arbor, MI 48104, as disclosed in the ownership filing for LABT.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 04:22 PM Accepted by SEC EDGAR 08/14/2026 - 04:15 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lakewood-Amedex Biotherapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

51255A201

(CUSIP Number)

05/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 51255A201

1

Names of Reporting Persons

WFI Equity, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MICHIGAN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,259,684.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,259,684.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,259,684.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: The percentage calculation is based on a total of 14,320,366 shares of Common Stock outstanding as of April 23, 2026, as indicated in the issuer's Form S-1 filing on May 1, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lakewood-Amedex Biotherapeutics Inc.
(b)	Address of issuer's principal executive offices: 8031 Cooper Creek Blvd., Unit 103, University Park, FL 34201
Item 2.
(a)	Name of person filing: WFI Equity, LLC
(b)	Address or principal business office or, if none, residence: 320 N. Main St., Suite 200 Ann Arbor, MI 48104
(c)	Citizenship: Michigan limited liability company
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 51255A201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,259,684
(b)	Percent of class: 8.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1,259,684
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1,259,684
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.	Certifications:
	Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

WFI Equity, LLC

Signature:	/s/ Bradford Charles Lichota
Name/Title:	Bradford Charles Lichota/Manager
Date:	08/14/2026